Acta Pharmaceutica Sinica B

Scope & Guideline

Pioneering Innovations in Drug Development

Introduction

Delve into the academic richness of Acta Pharmaceutica Sinica B with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN2211-3835
PublisherINST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
Support Open AccessYes
CountryChina
TypeJournal
Converge2012, from 2014 to 2024
AbbreviationACTA PHARM SIN B / Acta Pharm. Sin. B
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressC/O EDITORIAL BOARD OF ACTA PHARMACEUTICA SINICA, 1 XIANNONGTAN ST, BEIJING 100050, PEOPLES R CHINA

Aims and Scopes

Acta Pharmaceutica Sinica B is a leading journal that focuses on the intersection of pharmaceutical sciences and biotechnology, emphasizing innovative drug discovery, development, and delivery methods. The journal aims to publish high-quality research that advances the understanding of medicinal chemistry, pharmacology, and therapeutic applications.
  1. Drug Discovery and Development:
    The journal covers innovative approaches in drug discovery, including small molecules, biologics, and traditional medicines, emphasizing their mechanisms of action and therapeutic potential.
  2. Nanomedicine and Drug Delivery Systems:
    Significant focus on nanotechnology for drug delivery, exploring the design, synthesis, and application of nanocarriers to enhance therapeutic efficacy and reduce side effects.
  3. Pharmacology and Toxicology:
    Research on the pharmacokinetics, pharmacodynamics, and toxicological evaluations of new drugs, providing insights into their safety and efficacy profiles.
  4. Biotechnology and Molecular Biology:
    Studies that leverage biotechnological advancements, including CRISPR and gene editing, for therapeutic purposes, particularly in cancer and genetic diseases.
  5. Phytochemistry and Natural Products:
    Exploration of bioactive compounds from natural sources, including their pharmacological effects, mechanisms of action, and potential for drug development.
  6. Clinical Translational Research:
    Research that bridges laboratory findings with clinical applications, focusing on the development of new therapeutic strategies and improving patient outcomes.
Acta Pharmaceutica Sinica B has seen a surge in research themes that reflect the latest trends and advancements in pharmaceutical sciences. These emerging scopes indicate a shift towards innovative methodologies and therapeutic strategies.
  1. Immunotherapy and Checkpoint Inhibition:
    Research focusing on immunotherapy, especially combination therapies that enhance immune response against tumors, has gained significant traction, indicating a paradigm shift in cancer treatment.
  2. Nanomedicine Innovations:
    There is a growing trend in the development of novel nanomedicine platforms for targeted drug delivery, including stimuli-responsive systems that enhance therapeutic efficacy and minimize side effects.
  3. CRISPR and Gene Editing Technologies:
    The application of CRISPR and other gene-editing technologies in drug development and disease treatment has emerged as a prominent theme, highlighting the potential for genetic therapies.
  4. Microbiome Research:
    Studies exploring the role of the gut microbiome in drug metabolism and therapeutic responses are gaining importance, reflecting a broader interest in personalized medicine.
  5. Artificial Intelligence in Drug Discovery:
    The integration of AI and machine learning in drug discovery processes is becoming increasingly prevalent, showcasing efforts to improve efficiency and accuracy in identifying potential drug candidates.
  6. Sustainable and Green Chemistry:
    Research emphasizing sustainable practices in drug development, including the use of renewable resources and eco-friendly processes, is on the rise, aligning with global sustainability goals.

Declining or Waning

While Acta Pharmaceutica Sinica B continues to thrive in numerous research areas, certain themes have shown signs of declining interest or publication frequency. These waning scopes reflect shifts in research focus and the evolving landscape of pharmaceutical sciences.
  1. Traditional Drug Formulations:
    There has been a noticeable decline in studies focused on traditional drug formulations, as research shifts toward novel delivery systems and advanced drug formulations.
  2. Conventional Chemotherapy Approaches:
    The focus on conventional chemotherapy methods is waning in favor of targeted therapies and immunotherapies, indicating a shift toward more personalized medicine.
  3. Basic Pharmacognosy Studies:
    Research specifically centered on pharmacognosy without the application of modern techniques or translational potential has decreased, as the field moves towards integrating pharmacognosy with molecular biology.
  4. Single-Drug Therapy Studies:
    The decline in publications focusing solely on single-drug therapies suggests a growing interest in combination therapies and multi-target approaches to enhance treatment efficacy.

Similar Journals

Ars Pharmaceutica

Fostering collaboration for transformative pharmaceutical insights.
Publisher: UNIV GRANADA, EDITORIALISSN: 0004-2927Frequency: 4 issues/year

Ars Pharmaceutica is a distinguished open-access journal published by UNIV GRANADA, EDITORIAL, that has been at the forefront of pharmaceutical sciences since its establishment. With ISSN 0004-2927 and E-ISSN 2340-9894, this journal aims to disseminate high-quality research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of the field. With a historical scope that spans from 1980 to 2017, it has played a pivotal role in shaping the discourse surrounding pharmaceutical science and its intersection with the arts and humanities. Although currently ranked within the 13th percentile in Scopus for Pharmaceutical Science and the 11th percentile for History and Philosophy of Science, Ars Pharmaceutica continues to uphold its commitment to academic excellence and innovation. By providing a platform for open-access research, it encourages collaboration and knowledge sharing among researchers, professionals, and students, thus enhancing the broader understanding of pharmaceutical developments and their societal implications.

JOURNAL OF PHARMACEUTICAL SCIENCES

Connecting scholars and professionals to drive pharmaceutical excellence.
Publisher: ELSEVIER SCIENCE INCISSN: 0022-3549Frequency: 12 issues/year

The JOURNAL OF PHARMACEUTICAL SCIENCES, published by ELSEVIER SCIENCE INC, stands as a cornerstone in the field of pharmaceutical sciences, offering a platform for innovative research and advancements since its inception in 1961. With an impressive Scopus Rank of #36 out of 183 in the Pharmaceutical Science category, this journal is recognized for its commitment to disseminating high-quality, peer-reviewed studies that significantly contribute to the realms of pharmacology, toxicology, and pharmaceutics. Holding a 2023 Q2 category quartile, it attracts a diverse readership encompassing researchers, industry professionals, and students eager to advance their understanding and expertise. While the journal is not open access, it ensures valuable insights in every issue, making it an essential resource for those dedicated to the evolving landscape of pharmaceutical research. With an impact factor that reflects its relevance and influence, the JOURNAL OF PHARMACEUTICAL SCIENCES continues to shape the discourse in its domain, fostering innovation and collaboration among scholars worldwide.

TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH

Advancing pharmaceutical innovation for tropical health.
Publisher: PHARMACOTHERAPY GROUPISSN: 1596-5996Frequency: 2 issues/year

Tropical Journal of Pharmaceutical Research is an esteemed open-access platform dedicated to advancing the field of pharmaceutical sciences, published by the Pharmacotherapy Group in Nigeria. With an ISSN of 1596-5996 and open access established since 2002, this journal serves as a critical resource for researchers, professionals, and students seeking to disseminate and access high-quality research in both pharmaceutical science and pharmacology. Despite its ranking in the third quartile (Q3) for Pharmaceutical Science and the fourth quartile (Q4) in Pharmacology as of 2023, the journal continues to stand out with its commitment to fostering significant dialogue and innovation in the scientific community. Anchored at the University of Benin, Faculty of Pharmacy, the journal invites contributions that explore novel pharmaceutical research, clinical applications, and drug development, playing a vital role in addressing health challenges that are particularly relevant to tropical regions. Researchers can look forward to publishing their findings in a journal that not only promotes the sharing of knowledge but also enhances the scientific discourse within a rapidly evolving field.

Indian Journal of Pharmaceutical Education and Research

Transforming the landscape of pharmaceutical sciences through research.
Publisher: ASSOC PHARMACEUTICAL TEACHERS INDIAISSN: 0019-5464Frequency: 4 issues/year

Indian Journal of Pharmaceutical Education and Research, published by the Association of Pharmaceutical Teachers of India, is a pivotal platform for scholarly discussion in the field of pharmacology, toxicology, and pharmaceutics. ISSN 0019-5464, this esteemed journal aims to foster the exchange of innovative research, clinical advancements, and educational practices within the pharmaceutical sciences community. As a Q3-ranked journal in its category as of 2023, it reflects a commitment to upholding the standards of academic excellence and contributes significantly to the ongoing development of pharmaceutical education. The journal is a valuable resource for researchers, professionals, and students, with content spanning various key areas including drug formulation, safety, and the latest trends in pharmaceutical education. By providing open access to its research and reviews, the journal ensures that vital information is disseminated widely, promoting collaboration and learning among stakeholders in the pharmaceutical sector. Based in Bangalore, India, the journal has been instrumental in highlighting regional research while fostering a global dialogue in pharmaceutical sciences. As it continues its journey from 2008 to 2024, it remains dedicated to impacting the field through rigorous peer-reviewed content and engaging with contemporary challenges in healthcare and education.

YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN

Innovating the future of pharmacology and toxicology.
Publisher: PHARMACEUTICAL SOC JAPANISSN: 0031-6903Frequency: 12 issues/year

YAKUGAKU ZASSHI - JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, published by the Pharmaceutical Society of Japan, is a key academic journal dedicated to advancing the field of pharmaceutical sciences. Established in 1961 and set to contribute until 2024, this journal publishes original research articles, reviews, and clinical studies that encompass a wide spectrum of topics within pharmacology, toxicology, and pharmaceutics. Although the journal operates under a traditional subscription model, it maintains a recognized reputation with an impact factor that is steadily aligned within its category quartiles—ranking Q3 in Pharmaceutical Science and Q4 in Pharmacology as of 2023. With Scopus rankings reflecting its competitive standing, YAKUGAKU ZASSHI serves as a vital resource for researchers, professionals, and students looking to engage with innovative findings and broaden their understanding of pharmaceutical methodologies and research practices. With a current focus on bridging scientific research with real-world applications, it seeks to foster collaboration and knowledge sharing within the pharmaceutical community.

Research in Pharmaceutical Sciences

Driving Collaboration in Pharmaceutical Sciences
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 1735-5362Frequency: 6 issues/year

Research in Pharmaceutical Sciences is a premier, peer-reviewed journal published by Wolters Kluwer Medknow Publications, dedicated to advancing the field of pharmacology, toxicology, and pharmaceutics. With an impact factor that positions it in the second quartile of its category (Q2) and a respectable rank of 23 out of 80 in Scopus, this journal serves as an essential platform for researchers, professionals, and students alike, providing open access since 2015 to a wealth of pioneering studies and comprehensive reviews. Based in Mumbai, India, the journal encompasses a diverse range of topics within the pharmaceutical sciences, offering insights that address both theoretical and practical challenges in drug development and safety. As it converges from 2009 to 2024, Research in Pharmaceutical Sciences continues to be a vital source of knowledge, promoting innovation and fostering collaboration within the global scientific community.

Journal of Reports in Pharmaceutical Sciences

Innovating Drug Development Through Groundbreaking Research.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2322-1232Frequency: 2 issues/year

Journal of Reports in Pharmaceutical Sciences is a pivotal publication in the realm of pharmaceutical research, disseminating innovative findings that cater to the evolving landscape of pharmacology, toxicology, and biomedical engineering. Published by Wolters Kluwer Medknow Publications, the journal serves as a bridge for scholars and practitioners aiming to enhance their understanding of drug development, therapeutic advances, and biopharmaceutical technologies. With an ISSN of 2322-1232 and E-ISSN 2322-5106, it has established its relevance from 2012 to 2022, occupying notable quartile rankings, including Q3 in Pharmacology, Toxicology, and Pharmaceutics. Despite being categorized in Q4 in some areas, the journal's commitment to quality research ensures it remains a respected platform for disseminating significant insights. Researchers, professionals, and students alike will find this journal an indispensable resource for staying updated on critical advancements in pharmaceutical sciences, making it a go-to source for impactful studies that shape industry practices and academic inquiries.

Iranian Journal of Pharmaceutical Research

Fostering a vibrant community of pharmaceutical researchers.
Publisher: BRIEFLANDISSN: 1735-0328Frequency: 4 issues/year

Welcome to the Iranian Journal of Pharmaceutical Research, a pioneering publication in the field of pharmacology, toxicology, and pharmaceutics, published by BRIEFLAND. Established in 2002, this journal has been a crucial platform for disseminating innovative research and scholarly articles, contributing significantly to the advancement of pharmaceutical sciences in Iran and beyond. With an impressive trajectory leading towards a convergence of knowledge by 2024, it proudly holds a Q3 ranking in Pharmacology (Medical) and a Q2 ranking in the broader realm of Pharmacology, Toxicology, and Pharmaceutics for 2023. The journal's influence is underscored by its Scopus rank of #25/80 in General Pharmacology, Toxicology, and Pharmaceutics, placing it within the 69th percentile, therefore appealing to researchers, professionals, and students alike. Although the journal operates under a non-open access model, it remains dedicated to providing high-quality research articles that explore the latest advancements in pharmaceutical sciences, making it an essential resource for anyone involved in this vibrant field of study.

CURRENT PHARMACEUTICAL DESIGN

Innovating Drug Discovery, Shaping Tomorrow's Therapies
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1381-6128Frequency: 46 issues/year

CURRENT PHARMACEUTICAL DESIGN is a leading journal in the fields of Drug Discovery and Pharmacology, published by Bentham Science Publishers Ltd in the dynamic United Arab Emirates. With an impressive historical span from 1995 to 2024, this journal serves as a vital platform for disseminating innovative research findings, breakthrough methodologies, and critical reviews that shape the future of pharmaceutical sciences. Ranked Q2 in both Drug Discovery and Pharmacology categories according to the 2023 metrics, it places itself within the top-tier percentile, catering to a diverse audience of researchers, industry professionals, and students. The journal’s commitment to high-quality research exploration is evidenced by its Scopus ranking, where it is positioned favorably within its category ranks. Although currently not Open Access, CURRENT PHARMACEUTICAL DESIGN remains an essential resource for those looking to stay at the forefront of pharmacological advancements and drug development strategies.

DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY

Championing Research for a Healthier Tomorrow
Publisher: TAYLOR & FRANCIS LTDISSN: 0363-9045Frequency: 12 issues/year

Drug Development and Industrial Pharmacy is a prestigious journal published by Taylor & Francis Ltd, focusing on the critical field of pharmaceutical sciences. With an ISSN of 0363-9045 and an E-ISSN of 1520-5762, the journal has been an essential resource for researchers and professionals since its inception in 1974. It occupies a crucial niche within Drug Discovery, Organic Chemistry, and Pharmaceutical Science, currently ranked in the second and third quartiles, reflecting its solid contribution to the field. The journal encompasses a wide array of topics, including drug development processes, formulation, and industrial manufacturing alongside cutting-edge research in pharmacology and toxicology. With a commendable Scopus ranking demonstrating high relevance—ranked #44 in Pharmaceutical Science—it serves as a vital forum for academia and industry to share innovative findings and methodologies. While it does not offer open access, the journal remains an invaluable resource for those seeking to advance their knowledge and enhance their research in pharmaceutical development.